DualityBio and Genentech (Roche) entered a collaboration and license agreement to develop next-generation antibody-drug conjugates built around DualityBio’s DUPAC payload platform. The deal includes $45 million upfront and milestone payments that could exceed $1 billion, with tiered royalties. DualityBio will lead discovery and early-stage global clinical development through Phase I, while Genentech will take over broader clinical development and commercialization. The arrangement targets resistance to older topoisomerase inhibitor payloads and aims to improve activity in earlier-line settings where unmet need is rising.